Curcumin

Curcumin is the main curcuminoid in turmeric (Curcuma longa) — the yellow polyphenol behind the spice's colour and the molecule behind almost all of turmeric's measured health effects. Turmeric root is only about 2-5% curcuminoids by weight, which is why "turmeric" and "curcumin" are not interchangeable: a teaspoon of culinary turmeric delivers a tiny, sub-therapeutic curcumin dose, while the supplement category is standardised concentrated extract (typically 95% curcuminoids).

The defining problem with curcumin is bioavailability. Plain curcumin is poorly water-soluble, badly absorbed in the gut, rapidly metabolised by the liver, and quickly excreted — so a large fraction of a standard capsule never reaches the bloodstream. This is the single most important thing a buyer needs to understand, because it splits the market into products that work and products that don't. The clinical trials almost never used plain curcumin; they used absorption-enhanced formulations: curcumin plus piperine (black-pepper extract, which slows curcumin's metabolic clearance), or branded phospholipid/micellar/nanoparticle systems (Meriva, Longvida, BCM-95, Theracurmin) engineered specifically to raise blood levels many-fold over the raw compound.

So the practical definition of a useful curcumin supplement is: a standardised 95%-curcuminoid extract delivered in a bioavailability-enhanced form. "Turmeric 500 mg" on a budget label, with no curcuminoid percentage and no absorption enhancer, is the product to skip — it's the form the evidence base did not test.

Curcumin's anti-inflammatory action is broad and multi-target rather than a single mechanism. Its best-characterised lever is inhibition of NF-κB, the master transcription factor that switches on inflammatory gene programs; by damping NF-κB signalling, curcumin lowers downstream production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and inflammatory enzymes (COX-2, 5-LOX, iNOS). This is mechanistically distinct from NSAIDs, which block COX enzymes directly — curcumin works further upstream, which is part of why it produces a comparable pain effect with a very different (and generally gentler) side-effect profile.

The clinical payoff shows up most clearly in osteoarthritis. Kuptniratsaikul 2014 (PMID 24672232) randomised knee-OA patients to a standardised Curcuma domestica extract versus ibuprofen and found the curcumin arm non-inferior on pain and function — with significantly fewer gastrointestinal adverse events than ibuprofen. The Daily 2016 meta-analysis (PMID 27533649) pooled the arthritis RCTs and concluded that roughly 1,000 mg/day of curcumin produced meaningful reductions in pain (VAS) and WOMAC scores versus placebo. Wang 2021 (PMID 33511486) reached the same direction in a more recent systematic review of turmeric extracts for knee OA: real symptomatic benefit with a favourable safety profile.

Beyond joints, the same NF-κB / cytokine down-regulation is why curcumin is studied for systemic inflammation — trials report reductions in circulating inflammatory markers such as CRP. The effect size is real but dose- and formulation-dependent: it is a genuine anti-inflammatory, not a painkiller you feel in an hour, and the benefits accrue over weeks of consistent dosing with an absorbable product.